PRAX (Praxis Precision Medicines) Institutional Ownership: 119.50% (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $314.42
GF Value $25.66
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Praxis Precision Medicines Institutional Ownership?

Praxis Precision Medicines PRAX +2.01% 38 Institutional Ownership is 119.50% as of Jul. 18, 2026. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $25.66 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Praxis Precision Medicines's institutional ownership is 119.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Praxis Precision Medicines's Insider Ownership is 2.92%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Praxis Precision Medicines's Float Percentage Of Total Shares Outstanding is 99.76%.

Praxis Precision Medicines Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Praxis Precision Medicines's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Praxis Precision Medicines Institutional Ownership Chart

Praxis Precision Medicines Historical Data

The historical data trend for Praxis Precision Medicines can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 43.09 47.54 49.37 55.81 55.17 55.05 61.11 61.25 61.71 65.99
PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Praxis Precision Medicines Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 119.50% mean?
Praxis Precision Medicines (PRAX) has a Institutional Ownership of 119.50% as of Jul. 18, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Praxis Precision Medicines and its competitors.
Is Praxis Precision Medicines' Institutional Ownership too high?
Praxis Precision Medicines' current Institutional Ownership is 119.50%. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' Institutional Ownership compare to IBRX and CORT?
Praxis Precision Medicines' Institutional Ownership of 119.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Praxis Precision Medicines and its competitors. Praxis Precision Medicines's current Institutional Ownership is 119.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.66, compared to a current price of $314.42 — trading 1125.3% above its estimated fair value. The current Institutional Ownership is 119.50%. Praxis Precision Medicines' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current Institutional Ownership is 119.50% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $314.42 is trading 1125.3% above its estimated GF Value™ of $25.66. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Institutional Ownership: 119.50%
  • GF Value™: $25.66 vs. price of $314.42 (1125.3% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$314.42
Price
$25.66
GF Value